...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Breast Cancer >Efficacy and Safety Profile of Combining Sorafenib with Chemotherapy in Patients with HER2-Negative Advanced Breast Cancer: A Meta-analysis
【24h】

Efficacy and Safety Profile of Combining Sorafenib with Chemotherapy in Patients with HER2-Negative Advanced Breast Cancer: A Meta-analysis

机译：索拉非尼与化疗结合疗效和安全性曲线治疗患者的疗效和安全性分析：META分析

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose The aim of the study was to evaluate the efficacy and safety of combining sorafenib with chemotherapy in patients with human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. Methods MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, American Society for Clinical Oncology abstracts, and European Society for Medical Oncology abstracts were searched. Randomized clinical trials that compared the efficacy and safety of sorafenib plus chemotherapy in patients with HER2-negative advanced breast cancer with placebo plus chemotherapy were eligible. The endpoints were progression-free survival (PFS), overall survival (OS), time to progression (TTP), duration of response (DOR), overall response rate (ORR), clinical benefits, and adverse effects. The meta-analysis was performed using Review Manager 5.2.6 (The Nordic Cochrane Centre), and the fixed-effect model weighted by the Mantel-Haenszel method was used. When considerable heterogeneity was found ( p Results The final analysis included four trials comprising 844 patients. The results revealed longer PFS and TTP, and higher ORR and clinical benefit rates in patients receiving sorafenib combined with chemotherapy compared to those receiving chemotherapy and placebo. OS and DOR were similar in the two groups. Meanwhile, the incidence of some adverse effects, including hand-foot skin reaction/hand-foot syndrome, diarrhea, rash, and hypertension, were significantly higher in the sorafenib arm. Conclusion Sorafenib combined with chemotherapy may prolong PFS and TTP. This treatment was associated with manageable toxicities, but frequent dose interruptions and reductions were required.
机译：目的该研究的目的是评估索拉非尼与化疗结合人体表皮生长因子受体2（HER2）的高级乳腺癌的疗效的疗效和安全性。方法搜索了对照试验，美国临床肿瘤学会和欧洲医学肿瘤学会的临床试验中的Cochrane中央登记。随机化的临床试验比较了Sorafenib Plus化疗与Heldbo Plus化疗患者Her2阴性晚期乳腺癌患者的疗效和安全性。终点是无进展的存活率（PFS），总体存活（OS），进展时间（TTP），响应持续时间（DOR），整体反应率（ORR），临床效益和不利影响。使用审查管理器5.2.6（北斗Cochrane中心）进行META分析，使用由Mantel-Haenszel方法加权的固定效果模型。当发现相当大的异质性时（P结果最终分析包括含有844名患者的四次试验。结果显示了与接受化疗和安慰剂相比，患者与化疗相结合的患者的较长的PFS和TTP，更高的ORR和临床效益率。OS和两组中的Dor类似。同时，Sorafenib手臂的一些不良反应的发生率，包括手足皮肤反应/手足综合征，腹泻，皮疹和高血压。结论Sorafenib结合化疗可能延长PFS和TTP。该处理与可管理的毒性有关，但需要频繁的剂量中断和降低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号